Physician profile
Frederick S Fish
NPI 1346281250
$426.63
in general payments reported to CMS, 2019-2025
16 companies · $61.08 in 2025
The $61.08 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.41 · 2021: $23.98 · 2022: $16.28 · 2023: $193 · 2024: $66.90 · 2025: $61.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $139.44 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Mimedx Group, INC. | $34.10 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $31.09 | 2023 | Sotyktu |
| Mylan Institutional INC. | $29.63 | 2023 | Hulio |
| Abbvie INC. | $25.34 | 2024 | |
| Ucb, INC. | $24.73 | 2019 | |
| Dermavant Sciences, INC. | $17.79 | 2023 | Vtama |
| Lilly USA, LLC | $16.28 | 2022 | |
| Dusa Pharmaceuticals, INC. | $16.10 | 2019 | |
| Janssen Biotech, INC. | $15.62 | 2023 | Tremfya |
| Smith+Nephew, INC. | $14.81 | 2025 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $13.14 | 2023 | |
| Galderma Laboratories, L.P. | $12.81 | 2019 | |
| Genzyme Corporation | $12.15 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.83 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.